Certara (NASDAQ:CERT) Stock Rating Upgraded by UBS Group

Key Points

• UBS Group upgraded Certara to “hold,” while analysts’ overall consensus remained “Hold” with a $8.45 price target.
• Certara’s shares opened at $9.20, with the stock trading above its 50-day and 200-day moving averages; shares were down 0.6% in the session.
• The company missed quarterly expectations, reporting $0.08 EPS versus $0.09 expected and revenue of $93.27 million versus $98.09 million, with revenue down 10.8% year over year.

Certara (NASDAQ:CERT - Get Free Report) was upgraded by stock analysts at UBS Group to a "hold" rating in a research note issued on Wednesday, Zacks reports.

Several other research analysts have also recently weighed in on CERT. Barclays upped their price target on shares of Certara from $6.50 to $7.50 and gave the stock an "equal weight" rating in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of Certara from a "sell (e+)" rating to a "sell (d)" rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $8.45.

Certara Trading Down 0.6%

Shares of CERT stock opened at $9.20 on Wednesday. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of -20.44 and a beta of 1.40. The company's fifty day simple moving average is $8.19 and its two-hundred day simple moving average is $6.72. Certara has a 1 year low of $4.45 and a 1 year high of $13.88. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). The company had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business's revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.07 earnings per share. As a group, analysts anticipate that Certara will post 0.22 earnings per share for the current year.

Institutional Investors Weigh In On Certara

A number of large investors have recently made changes to their positions in CERT. BlackRock Inc. bought a new stake in shares of Certara during the second quarter valued at approximately $123,259,000. Haveli Investment Management LLC purchased a new stake in shares of Certara in the second quarter worth $48,470,000. Jefferies Financial Group Inc. purchased a new position in shares of Certara in the 2nd quarter worth about $46,446,000. Bank of America Corp DE bought a new stake in Certara during the 2nd quarter valued at about $11,780,000. Finally, Tejara Capital Ltd bought a new position in shares of Certara in the second quarter worth approximately $8,467,000. 73.96% of the stock is currently owned by institutional investors.

About Certara

Certara NASDAQ: CERT provides software and technology-enabled services that support the development, approval and commercialization of medicines. The company specializes in model-informed drug development, using pharmacometrics, simulation, data analysis and regulatory science to help biopharmaceutical companies evaluate drug safety, efficacy, dosing and potential regulatory outcomes.

Its software portfolio includes platforms such as Simcyp, which supports clinical pharmacology and drug-interaction modeling; Phoenix, used for pharmacokinetic and pharmacodynamic analysis; and Pinnacle 21, which helps organizations manage clinical data standards and regulatory submissions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.